Pathogenesis of ankylosing spondylitis: Current concepts

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 3, 2006, Pages 571-591

  Smith, Judith A ^a   Märker Hermann, Elisabeth ^a   Colbert, Robert A ^b  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

arthritogenic peptide; heavy chain dimers; HLA B27 misfolding; macrophages; toll like receptors; unfolded protein response

Indexed keywords

BETA 2 MICROGLOBULIN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA B27 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ANKYLOSING SPONDYLITIS; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ARTHRITIS; B LYMPHOCYTE; BACTERIAL FLORA; BACTERIAL SURVIVAL; BACTEROIDES; CAMPYLOBACTER; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CHLAMYDIA; CLINICAL FEATURE; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM INFLAMMATION; ENDOPLASMIC RETICULUM; EXPERIMENTAL MODEL; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INTESTINE FLORA; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FOLDING; RAT; REVIEW; SALMONELLA; SHIGELLA; T LYMPHOCYTE; TH1 CELL;

ANIMALS; DISEASE MODELS, ANIMAL; HLA-B27 ANTIGEN; HUMANS; PROTEIN FOLDING; RHEUMATOLOGY; SPONDYLITIS, ANKYLOSING;

EID: 33746897749     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.03.001     Document Type: Review

References (118)

1. Schlosstein L., Terasaki P.I., Bluestone R., and Pearson C.M. High association of an HL-A antigen, W27, with ankylosing spondylitis. The New England Journal of Medicine 288 (1973) 704-706
2. Brewerton D.A., Hart F.D., Nicholls A., et al. Ankylosing spondylitis and HL-A 27. Lancet 1 (1973) 904-907
3. Sims A.M., Wordsworth B.P., and Brown M.A. Genetic susceptibility to ankylosing spondylitis. Current Molecular Medicine 4 (2004) 13-20
4. Francois R.J., Gardner D.L., Degrave E.J., and Bywaters E.G. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis and Rheumatism 43 (2000) 2011-2024
5. Braun J., Bollow M., Neure L., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis and Rheumatism 38 (1995) 499-505
6. Bollow M., Fischer T., Reisshauer H., et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T-cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancementdetected by magnetic resonance imaging. Annals of the Rheumatic Diseases 59 (2000) 135-140
7. Baeten D., and De Keyser F. The histopathology of spondyloarthropathy. Current Molecular Medicine 4 (2004) 1-12
8. Veale D., Yanni G., Rogers S., et al. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis and Rheumatism 36 (1993) 893-900
9. Reece R.J., Canete J.D., Parsons W.J., et al. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis and Rheumatism 42 (1999) 1481-1484
10. Baeten D., Demetter P., Cuvelier C., et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Annals of the Rheumatic Diseases 59 (2000) 945-953
11. Baeten D., Demetter P., Cuvelier C.A., et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. The Journal of Pathology 196 (2002) 343-350
12. Smeets T.J., Dolhain R.J., Breedveld F.C., and Tak P.P. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. The Journal of Pathology 186 (1998) 75-81
13. Kraan M.C., Haringman J.J., Post W.J., et al. Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis. Rheumatology (Oxford, England) 38 (1999) 1074-1080
14. Baeten D., Moller H.J., Delanghe J., et al. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis and Rheumatism 50 (2004) 1611-1623
15. Seta N., Granfors K., Sahly H., et al. Expression of host defense scavenger receptors in spondylarthropathy. Arthritis and Rheumatism 44 (2001) 931-939
16. Laloux L., Voisin M.C., Allain J., et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Annals of the Rheumatic Diseases 60 (2001) 316-321
17. McGonagle D., Marzo-Ortega H., O'Connor P., et al. Histological assessment of the early enthesitis lesion in spondyloarthropathy. Annals of the Rheumatic Diseases 61 (2002) 534-537
18. Kievits F., Ivanyi P., Krimpenfort P., et al. HLA-restricted recognition of viral antigens in HLA transgenic mice. Nature 329 (1987) 447-449
19. Krimpenfort P., Rudenko G., Hochstenbach F., et al. Crosses of two independently derived transgenic mice demonstrate functional complementation of the genes encoding heavy (HLA-B27) and light (β2-microglobulin) chains of HLA class I antigens. The EMBO Journal 6 (1987) 1673-1676
20. Weinreich S., Hoebe-Hewryk B., van der Horst A.R., et al. The role of MHC class I heterodimer expression in mouse ankylosing enthesopathy. Immunogenetics 46 (1997) 35-40
21. Rehakova Z., Capkova J., Stepankova R., et al. Germ-free mice do not develop ankylosing enthesopathy, a spontaneous joint disease. Human Immunology 61 (2000) 555-558
22. 2-microglobulin: a model of human spondyloarthropathies. The Journal of Experimental Medicine 182 (1995) 1153-1158
23. 2-m: an animal model of HLA-B27-associated human disorders. Cell 63 (1990) 1099-1112
24. Taurog J.D., Maika S.D., Satumtira N., et al. Inflammatory disease in HLA-B27 transgenic rats. Immunological Reviews 169 (1999) 209-223
25. Breban M., Hammer R.E., Richardson J.A., and Taurog J.D. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. The Journal of Experimental Medicine 178 (1993) 1607-1616
26. Breban M., Fernandez-Sueiro J.L., Richardson J.A., et al. T-cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. Journal of Immunology 156 (1996) 794-803
27. May E., Dorris M.L., Satumtira N., et al. CD8αβ T-cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. Journal of Immunology 170 (2003) 1099-1105
28. Taurog J.D., Richardson J.A., Croft J.T., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. The Journal of Experimental Medicine 180 (1994) 2359-2364
29. 2 microglobulin transgenic rats. The Journal of Clinical Investigation 98 (1996) 945-953
30. Rath H.C., Wilson K.H., and Sartor R.B. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infection and Immunity 67 (1999) 2969-2974
31. Sartor R.B. Colitis in HLA-B27/beta 2 microglobulin transgenic rats. International Reviews of Immunology 19 (2000) 39-50
32. Dieleman L.A., Hoentjen F., Qian B.F., et al. Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats. Clinical and Experimental Immunology 136 (2004) 30-39
33. Colmegna I., Cuchacovich R., and Espinoza L.R. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clinical Microbiology Reviews 17 (2004) 348-369
34. De Keyser F., Elewaut D., De Vos M., et al. Bowel inflammation and the spondyloarthropathies. Rheumatic Diseases Clinics of North America 24 (1998) 785-813
35. Lionetti P., Pupi A., Veltroni M., et al. Evidence of subclinical intestinal inflammation by 99mtechnetium leukocyte scintigraphy in patients with HLA-B27 postiive juvenile onset active spondyloarthropathy. The Journal of Rheumatology 27 (2000)
36. Demetter P., De Vos M., Van Huysse J.A., et al. Colon mucosa of both spondyloarthritis and Crohn's disease patients is enriched with macrophages expressing the scavenger receptor CD163. Annals of the Rheumatic Diseases 64 (2005) 321-324
37. De Keyser F., Baeten D., Van den Bosch F., et al. Gut inflammation and spondyloarthropathies. Current Rheumatology Reports 4 (2002) 525-532
38. Keller C., Webb A., and Davis J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Annals of the Rheumatic Diseases 62 (2003) 1128-1132
39. Sonel B., Tutkak H., and Duzgun N. Serum levels of IL-1 beta, TNF-alpha, IL-8, and acute phase proteins in seronegative spondyloarthropathies. Joint, Bone, Spine 69 (2002) 463-467
40. Gratacos J., Collado A., Filella X., et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. British Journal of Rheumatology 33 (1994) 927-931
41. Claudepierre P., Rymer J.C., and Chevalier X. IL-10 plasma levels correlate with disease activity in spondyloarthropathy. The Journal of Rheumatology 24 (1997) 1659-1661
42. Bas S., Kvien T.K., Buchs N., et al. Lower level of synovial fluid interferon-gamma in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis. Rheumatology (Oxford, England) 42 (2003) 461-467
43. Rudwaleit M., Siegert S., Yin Z., et al. Low T-cell production of TNFα and IFN γ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Annals of the Rheumatic Diseases 60 (2001) 36-42
44. Zou J., Rudwaleit M., Brandt J., et al. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T-cells in ankylosing spondylitis during treatment with etanercept. Annals of the Rheumatic Diseases 62 (2003) 561-564
45. Zou J., Rudwaleit M., Brandt J., et al. Down-regulation of the nonspecific and antigen-specific T-cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis and Rheumatism 48 (2003) 780-790
46. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nature Immunology 5 (2004) 987-995
47. Akira S., and Takeda K. Toll-like receptor signalling. Nature Reviews. Immunology 4 (2004) 499-511
48. Corr M. The tolls of arthritis. Arthritis and Rheumatism 52 (2005) 2233-2236
49. Gautier G., Humbert M., Deauvieau F., et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. The Journal of Experimental Medicine 201 (2005) 1435-1446
50. Yamamoto M., Sato S., Hemmi H., et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301 (2003) 640-643
51. Asea A., Rehli M., Kabingu E., et al. Novel signal transduction pathway utilized by extracellular HSP70: role of Toll-like receptor (TLR) 2 and TLR4. The Journal of Biological Chemistry 277 (2002) 15028-15034
52. Okamura Y., Watari M., Jerud E.S., et al. The extra domain A of fibronectin activates Toll-like receptor 4. The Journal of Biological Chemistry 276 (2001) 10229-10233
53. Beg A.A. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends in Immunology 23 (2002) 509-512
54. Radstake T.R., Roelofs M.F., Jenniskens Y.M., et al. Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis and Rheumatism 50 (2004) 3856-3865
55. De Rycke L., Vandooren B., Kruithof E., et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis and Rheumatism 52 (2005) 2146-2158
56. Cario E., and Podolsky D.K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infection and Immunity 68 (2000) 7010-7017
57. Benjamin R.J., and Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunology Today 11 (1990) 137-142
58. Edwards J.C.W., Bowness P., and Archer J.R. Jekyll and Hyde: the transformation of HLA-B27. Immunology Today 21 (2000) 256-260
59. Colbert R.A. HLA-B27 misfolding: a solution to the spondyloarthropathy conundrum?. Molecular Medicine Today 6 (2000) 224-230
60. Penttinen M.A., Ekman P., and Granfors K. Non-antigen presenting effects of HLA-B27. Current Molecular Medicine 4 (2004) 41-49
61. Ringrose J.H. HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?. Annals of the Rheumatic Diseases 58 (1999) 598-610
62. Hermann E., Yu D.T.Y., Meyer zum Buschenfelde K.-H., and Fleischer B. HLA-B27-restricted CD8 T-cells from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 342 (1993) 646-650
63. Ugrinovic S., Mertz A., Wu P., et al. A single nonamer from the yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in yersinia-induced reactive arthritis. Journal of Immunology 159 (1997) 5715-5723
64. Kuon W., Holzhutter H.-G., Appel H., et al. Identification of HLA-B27-restricted peptides from Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated disease. Journal of Immunology 167 (2001) 4738-4746
65. Duchmann R., Lambert C., May E., et al. CD4+ and CD8+ clonal T-cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins. Clinical and Experimental Immunology 123 (2001) 315-322
66. Scofield R.H., Kurien B., Gross T., et al. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 345 (1995) 1542-1544
67. Frauendorf E., von Goessel H., May E., and Marker-Hermann E. HLA-B27-restricted T-cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clinical and Experimental Immunology 134 (2003) 351-359
68. +T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. The Journal of Clinical Investigation 106 (2000) 47-53
69. Hülsmeyer M., Fiorillo M.T., Bettosini F., et al. Dual, HLA-B27 subtype-dependent conformation of a self-peptide. The Journal of Experimental Medicine 199 (2004) 271-281
70. Leishman A.J., Naidenko O.V., Attinger A., et al. T-cell responses modulated through interaction between CD8alphaalpha and the nonclassical MHC class I molecule, TL. Science 294 (2001) 1936-1939
71. 2-microglobulin-free heavy chain homodimer structure. Journal of Immunology 162 (1999) 5045-5048
72. Bird L.A., Peh C.A., Kollnberger S., et al. Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. European Journal of Immunology 33 (2003) 748-759
73. Malik P., Klimovitsky P., Deng L.W., et al. Uniquely conformed peptide-containing beta 2-microglobulin-free heavy chains of HLA-B2705 on the cell surface. Journal of Immunology 169 (2002) 4379-4387
74. Dangoria N.S., DeLay M.L., Kingsbury D.J., et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. The Journal of Biological Chemistry 277 (2002) 23459-23468
75. Kollnberger S., Bird L.A., S M.-Y., et al. Cell surface expression and immune receptor recogntion of HLA-B27 homodimers. Arthritis and Rheumatism 46 (2002) 2972-2982
76. Kollnberger S., Bird L.A., Roddis M., et al. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. Journal of Immunology 173 (2004) 1699-1710
77. Chan A.T., Kollnberger S.D., Wedderburn L.R., and Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis and Rheumatism 52 (2005) 3586-3595
78. Boyle L.H., Goodall J.C., Opat S.S., and Gaston J.S.H. The recognition of HLA-B27 by human CD4+T lymphocytes. Journal of Immunology 167 (2001) 2619-2624
79. Virtala M., Kirveskari J., and Granfors K. HLA-B27 modulates the survival of Salmonella enteritidis in transfected L cells, possibly by impaired nitric oxide production. Infection and Immunity 65 (1997) 2436-4242
80. Laitio P., Virtala M., Salmi M., et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. European Journal of Immunology 27 (1997) 1331-1338
81. Penttinen M.A., Heiskanen K.M., Mohapatra R., et al. Enhanced intracellular replication of Salmonella enteritidis in HLA-B27-expressing human monocytic cells: dependency on glutamic acid at position 45 in the B pocket of HLA-B27. Arthritis and Rheumatism 50 (2004) 2255-2263
82. Saarinen M., Ekman P., Ikeda M., et al. Invasion of salmonella into human intestinal epithelial cells is modulated by HLA-B27. Rheumatology (Oxford, England) 41 (2002) 651-657
83. Huppertz H.I., and Heesemann J. Invasion and persistence of salmonella in human fibroblasts positive or negative for endogenous HLA B27. Annals of the Rheumatic Diseases 56 (1997) 671-676
84. Young J.L., Smith L., Matyszak M.K., and Gaston J.S.H. HLA-B27 expression does not modulate intracellular Chlamydia trachomatis infection of cell lines. Infection and Immunity 69 (2001) 6670-6675
85. Kuipers J.G., Bialowons A., Dollman P., et al. The modulation of chlamydial replication by HLA-B27 depends on the cytoplasmic domain of HLA-B27. Clinical and Experimental Rheumatology 19 (2001) 47-52
86. Mear J.P., Schreiber K.L., Munz C., et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. Journal of Immunology 163 (1999) 6665-6670
87. Antoniou A.N., Ford S., Taurog J.D., et al. Formation of HLA-B27 homodimers and their relationship to assembly kinetics. The Journal of Biological Chemistry 279 (2004) 8895-8902
88. Tran T.M., Satumtira N., Dorris M.L., et al. HLA-B27 in transgenic rats forms disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP. Journal of Immunology 172 (2004) 5110-5119
89. Colbert R.A., Rowland-Jones S.L., McMichael A.J., and Frelinger J.A. Allele-specific B pocket transplant in class I major histocompatibility complex protein changes requirement for anchor residue at P2 of peptide. Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 6879-6883
90. Colbert R.A. The immunobiology of HLA-B27: variations on a theme. Current Molecular Medicine 4 (2004) 21-30
91. Whelan M.A., and Archer J.R. Chemical reactivity of an HLA-B27 thiol group. European Journal of Immunology 23 (1993) 3278-3285
92. Schroder M., and Kaufman R.J. The mammalian unfolded protein response. Annual Review of Biochemistry 74 (2005) 739-789
93. Harding H.P., Calfon M., Urano F., et al. Transcriptional and translational control in the mammalian unfolded protein response. Annual Review of cell and Developmental Biology 18 (2002) 575-599
94. Turner M.J., Sowders D.P., DeLay M.L., et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. Journal of Immunology 175 (2005) 2438-2448
95. Deng J., Lu P.D., Zhang Y., et al. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Molecular and Cellular Biology 24 (2004) 10161-10168
96. Turner M.J., Sowders D.P., DeLay M.L., et al. HLA-B27 misfolding and induction by IFN-g activates the unfolded protein response which augments type I IFN production in macrophages from transgenic rats. Arthritis and Rheumatism 52 (2005) S691
97. Smith J.A., Turner M.J., Sowders D.P., et al. The endoplasmic reticulum stress-induced unfolded protein response sensitizes macrophages to TLR-dependent IFN-b production. Arthritis and Rheumatism 52 (2005) S393
98. Biron C.A. Interferons alpha and beta as immune regulators-a new look. Immunity 14 (2001) 661-664
99. Theofilopoulos A.N., Baccala R., Beutler B., and Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annual Review of Immunology 23 (2005) 307-336
100. Marrack P., Kappler J., and Mitchell T. Type I interferons keep activated T-cells alive. The Journal of Experimental Medicine 189 (1999) 521-530
101. Le Bon A., and Tough D.F. Links between innate and adaptive immunity via type I interferon. Current Opinion in Immunology 14 (2002) 432-436
102. Takayanagi H., Kim S., Matsuo K., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416 (2002) 744-749
103. Deonarain R., Verma A., Porter A.C., et al. Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proceedings of the National Academy of Sciences of the United States of America 100 (2003) 13453-13458
104. Tran T.M., Dorris M.L., Satumitra N., et al. Additional human beta-2m curbs HLA-B27 heavy chain misfolding and promotes arthritis and spondylitis but not colitis in male B27 transgenic rats. Arthritis and Rheumatism 52 (2005) S447
105. Miyata T., Hori O., Zhang J., et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. The Journal of Clinical Investigation 98 (1996) 1088-1094
106. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. The Journal of Clinical Investigation 108 (2001) 949-955
107. Majors A.K., Austin R.C., de la Motte C.A., et al. Endoplasmic reticulum stress induces hyaluronan deposition and leukocyte adhesion. The Journal of Biological Chemistry 278 (2003) 47223-47231
108. Ball E.J., and Khan M.A. HLA-B27 polymorphism. Joint, Bone, Spine 68 (2001) 378-382
109. D'Amato M., Fiorillo M.T., Carcassi C., et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. European Journal of Immunology 25 (1995) 3199-3201
110. Feltkamp T.E., Mardjuadi A., Huang F., and Chou C.T. Spondyloarthropathies in eastern Asia. Current Opinion in Rheumatology 13 (2001) 285-290
111. Olivieri I., Ciancio G., Padula A., et al. The HLA-B*2709 subtype confers susceptibility to spondyloarthropathy. Arthritis and Rheumatism 46 (2003) 553-554
112. Fiorillo M.T., Meadows L., D'Amato M., et al. Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. European Journal of Immunology 27 (1997) 368-373
113. Sesma L., Montserrat V., Lamas J., et al. The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B*2704 and B*2706) differ by specific changes at three anchor positions. The Journal of Biological Chemistry 277 (2002) 16744-16749
114. Ramos M., Paradela A., Vazquez M., et al. Differential association of HLA-B*2705 and B*2709 to ankylosing spondylitis correlates with limited peptide subsets but not with altered cell surface stability. The Journal of Biological Chemistry 277 (2002) 28749-28756
115. Goodall J.C., Ellis L., and Hill Gaston J.S. Spondylarthritis-associated and non-spondylarthritis-associated B27 subtypes differ in their dependence upon tapasin for surface expression and their incorporation into the peptide loading complex. Arthritis and Rheumatism 54 (2006) 138-147
116. Cauli A., Dessole G., Fiorillo M.T., et al. Increased level of HLA-B27 expression in ankylosing spondylitis patients compared with healthy HLA-B27-positive subjects: a possible further susceptibility factor for the development of disease. Rheumatology (Oxford, England) 41 (2002) 1375-1379
117. Cauli A., Dessole G., Cappai L., et al. The lack of association between HLA-B*2709 and ankylosing spondylitis is not due to a defective cellular expression of the B*2709 molecules. Arthritis and Rheumatism 52 (2005) S394
118. Fiorillo M.T., Cauli A., Carcassi C., et al. Two distinctive HLA haplotypes harbor the B27 alleles negatively or positively associated with ankylosing spondylitis in Sardinia: implications for pathogenesis. Arthritis and Rheumatism 48 (2003) 1385-1389